Publications by authors named "Dian-Rong Lu"
Background: Small cell lung cancer (SCLC) is a common and aggressive subtype of lung cancer. It is characterized by rapid growth and a high mortality rate. Approximately 10% of patients with SCLC present with brain metastases at the time of diagnosis, which is associated with a median survival of 5 mo.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors like PD-L1 and PD-1 have gained approval for treating advanced urothelial carcinoma (UC), but some patients may experience rapid tumor growth instead of improvement from these therapies.
- A case involving a 73-year-old woman with bladder UC showed that after receiving the anti-PD-L1 drug toripalimab and albumin-bound paclitaxel, her cancer progressed rapidly within two months, worsening her condition significantly.
- There’s a pressing need to identify patients who are likely to respond to immunotherapy, especially in older patients who have limited chemotherapy options; more research is necessary to understand the phenomenon of hyperprogression in these cases.
Objective: To observe the effectiveness and safety of electrothermal acupuncture therapy for patients of moderate to severe cancer pain with -cold stagnation.
Methods: A total of 60 patients of moderate to severe cancer pain with -cold stagnation were randomized into an observation group and a control group, 30 cases in each one. In the control group, opioid painkillers (oxycodone hydrochloride prolonged-release tablet or morphine sulfate sustained-release tablet) were taken.
Objective: To investigate the effect of Yishengukang decoction on the expression of the metabolic bone markers, bone-specific alkaline phosphatase (BAP), carboxyterminal propeptide of type Ⅰ procollagen (PICP), and arboxyterminal cross-linked telepeptide of type Ⅰ collagen (ICTP), in cancer patients with bone metastasis.
Methods: Patients (n = 180) were divided into three groups: (a) bone metastasis patients treated with Yishengukang and pamidronate disodium injection (treatment group, n = 60); (b) bone metastasis patients treated with pamidronate disodium injection alone (control group, n = 60); (c) cancer patients without metastatic bone lesion (non-bone metastasis group, n = 60). Serum levels of the metabolic markers BAP, PICP, and ICTP were detected by enzyme-linked immunosorbent assay pre- and post-therapy.
Objective: To observe the effects of Compound Zhebei Granules (CZG) in chemotherapy for refractory acute leukemia.
Method: Using a randomized, double-blind and multi-central concurrent control clinical research project, the patients conformed with the diagnostic criteria, according to the drug randomized method, were divided into a CZG group and a control group. The patients of the two groups respectively took the observation drug or a placebo 3 days before chemotherapy, and the therapeutic effects were evaluated after one course of chemotherapy.